ESPR Esperion Therapeutics Inc

Price (delayed)

$2.67

Market cap

$494.09M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.03

Enterprise value

$952.79M

Through scientific and clinical excellence, and a deep understanding of cholesterol biology, the experienced Lipid Management Team at Esperion is committed to developing new LDL-C lowering medicines that will make ...

Highlights
ESPR's revenue has surged by 54% year-on-year and by 13% since the previous quarter
The company's gross profit has surged by 51% YoY and by 9% QoQ
The quick ratio has plunged by 61% YoY and by 26% from the previous quarter
The equity has decreased by 41% YoY and by 11% QoQ

Key stats

What are the main financial stats of ESPR
Market
Shares outstanding
185.05M
Market cap
$494.09M
Enterprise value
$952.79M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
2.37
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.19
Earnings
Revenue
$116.33M
EBIT
-$150.27M
EBITDA
-$150.11M
Free cash flow
-$135.49M
Per share
EPS
-$2.03
Free cash flow per share
-$1.31
Book value per share
-$4
Revenue per share
$1.13
TBVPS
$2
Balance sheet
Total assets
$205.8M
Total liabilities
$660.79M
Debt
$540.95M
Equity
-$454.99M
Working capital
$44.84M
Liquidity
Debt to equity
-1.19
Current ratio
1.29
Quick ratio
0.84
Net debt/EBITDA
-3.06
Margins
EBITDA margin
-129%
Gross margin
62.8%
Net margin
-179.9%
Operating margin
-133.7%
Efficiency
Return on assets
-91.6%
Return on equity
N/A
Return on invested capital
-29.4%
Return on capital employed
-303.1%
Return on sales
-129.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ESPR stock price

How has the Esperion Therapeutics stock price performed over time
Intraday
1.91%
1 week
26.54%
1 month
3.89%
1 year
51.7%
YTD
-10.7%
QTD
-10.7%

Financial performance

How have Esperion Therapeutics's revenue and profit performed over time
Revenue
$116.33M
Gross profit
$73.07M
Operating income
-$155.56M
Net income
-$209.25M
Gross margin
62.8%
Net margin
-179.9%
ESPR's revenue has surged by 54% year-on-year and by 13% since the previous quarter
The company's gross profit has surged by 51% YoY and by 9% QoQ
ESPR's operating margin is up by 44% year-on-year and by 12% since the previous quarter
Esperion Therapeutics's net margin has increased by 42% YoY and by 11% QoQ

Growth

What is Esperion Therapeutics's growth rate over time

Valuation

What is Esperion Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
2.37
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.19
Esperion Therapeutics's EPS has increased by 42% YoY and by 14% QoQ
The equity has decreased by 41% YoY and by 11% QoQ
The price to sales (P/S) is 83% lower than the 5-year quarterly average of 13.8 but 36% higher than the last 4 quarters average of 1.7
ESPR's revenue has surged by 54% year-on-year and by 13% since the previous quarter

Efficiency

How efficient is Esperion Therapeutics business performance
Esperion Therapeutics's return on sales has increased by 45% YoY and by 11% QoQ
The return on assets has declined by 18% year-on-year and by 5% since the previous quarter
The return on invested capital has grown by 5% year-on-year

Dividends

What is ESPR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ESPR.

Financial health

How did Esperion Therapeutics financials performed over time
The total assets is 69% less than the total liabilities
The quick ratio has plunged by 61% YoY and by 26% from the previous quarter
The company's current ratio has shrunk by 52% YoY and by 18% QoQ
The equity has decreased by 41% YoY and by 11% QoQ
ESPR's debt to equity is up by 24% year-on-year and by 8% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.